Lundbeck gains worldwide rights to nalmefene
This article was originally published in Scrip
Executive Summary
Lundbeck has now gained the worldwide rights, excluding Turkey and South Korea, to Biotie Therapies' nalmefene after it acquired the North American and Mexican rights from Somaxon Pharmaceuticals. Lundbeck and Biotie are developing the investigational Phase III product for alcohol dependence.